FDA Begins Blazing Narrow Trail for Approval Shortcut
By Mari Serebrov
Tuesday, January 15, 2013
Hoping to beef up its arsenal against drug-resistant bacteria, the FDA is taking the first steps to blaze a new approval shortcut for drugs, both small molecules and biologics, that narrowly focus on serious or life-threatening diseases in which there's an unmet need.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.